The only active comparator ever used against cagrilintide monotherapy was liraglutide 3.0 mg in a Phase 2 study not tirzepatide so every ranking of the two is cross-trial inference across different populations and endpoints
Vaccines (Basel) 10 , 1735 (2022)
Epithalon has been investigated as a potential treatment for rheumatoid arthritis and ulcerative colitis due to its ability to regulate biomolecules involved in the inflammation process, such as cytokines and C-reactive protein [7]
In the Phase 2 obesity trial it produced about 24% weight loss at 12 mg over 48 weeks, the most of any drug in the class, and it cut liver fat by 86% in the people who started with fatty liver. In the 80-week Phase 3 obesity trial of 2,300 adults with an average BMI of 40, 12 mg produced 28% weight loss and 9 mg reached 26%
Dalton TP, Chen Y, Schneider SN, Nebert DW, Shertzer HG
Animal studies show no toxicity up to high doses, but human reports are anecdotal